BusinessAdamas to Present at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 28, 2017, 2:33 PM UTC
BusinessAdamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders CongressBy Nasdaq OMXFeb 28, 2017, 1:31 PM UTC
BusinessAdamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders CongressBy Nasdaq OMXFeb 28, 2017, 1:31 PM UTC
BusinessCempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSIBy Nasdaq OMXFeb 24, 2017, 12:00 PM UTC
BusinessSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsBy Nasdaq OMXFeb 1, 2017, 12:01 PM UTC
BusinessSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsBy Nasdaq OMXFeb 1, 2017, 12:01 PM UTC
BusinessEsperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with HypercholesterolemiaBy Nasdaq OMXJan 25, 2017, 1:05 PM UTC
BusinessAdvanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III ResultsBy Nasdaq OMXJan 12, 2017, 1:05 PM UTC
